From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
December 8, 2021
Philadelphia, PA, December 8, 2021 – IntegriChain, delivering Life Sciences’ only comprehensive data and business process platform for market access, today announced its annual customer awards to innovators and visionaries in market access and commercialization. The company awards included Market Access Visionary Award to Paratek Pharmaceuticals, Lighthouse Award to Agile Therapeutics, Zero to Launch Award to AVEO Oncology, the Launch Innovator Award to Moderna, and the Patient and Channel Data Trailblazer to Apellis Pharmaceuticals. An individual award, the ICyte Power User Award, was presented to Jane Daly, Manager of Demand Management at Novartis Pharmaceuticals.
“We are thrilled to celebrate the success and vision of our customers, Life Sciences groundbreakers who share our mission to help patients start and stay on therapy,” said IntegriChain Co-Founder and CEO Kevin Leininger. “We are very proud to have meaningful partnerships with our innovative customers as we continue to enhance and expand the unified ICyte data and analytics platform for commercialization and market access, and we are thrilled to highlight and honor the outstanding impact on patients – and even the world! – being made by these outstanding companies and the critical therapies they offer.”
Market Access Visionary: Paratek As Paratek worked toward the launch of NUZYRA®, a new antibiotic, it was important to the team to have consolidation of its market access and commercialization efforts. As such, they selected the unified ICyte Platform for Channel Data, Contracts and Pricing and Gross-to-Net. They also assisted IntegriChain as a customer-partner in the piloting of the Customer Success program.
Lighthouse Award: Agile As Agile Therapeutics readied to launch Twirla®, its weekly birth control patch, the Market Access and Finance teams were early adopters of ICyte Channel, Contracts and Pricing, and Gross-to-Net products. Throughout their launch readiness process and beyond, Agile was a collaborative partner with IntegriChain to optimize success of launch and commercialization in women’s health.
Zero to Launch: AVEO Oncology AVEO launched FOTIVDA® for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma earlier this year. They rapidly readied for launch with limited resources, partnering with IntegriChain to ensure they were day-1 ready.
Launch Innovator Award: Moderna Moderna’s ability to develop and launch its COVID-19 vaccine literally changed the world. They partnered with IntegriChain for launch-readiness Advisory Services as well as Government Pricing and State Pricing Transparency, in support of future commercial launch.
Patient and Channel Data Trailblazer Award: Apellis Apellis launched EMPAVELI for rare disease, relying on IntegriChain for both Patient and Channel data. IntegriChain has valued immensely the input from the Apellis team to improve and innovate ICyte data products.
ICyte Power User 2021: Jane Daly, Novartis IntegriChain named Jane Daly, Manager, Demand Management, for Novartis as the ICyte Power User for 2021. Throughout the year, Daly was a consistently engaged user on the ICyte data and analytics platform and with IntegriChain’s Customer Support team, partnering on innovation and new enhancements to ICyte.
About IntegriChain IntegriChain is Life Sciences’ data and application backbone for patient access and therapy commercialization. More than 250 manufacturers rely on IntegriChain’s ICyte Platform to orchestrate commercial and government payer contracting, patient services, and distribution channels. ICyte is the first and only platform that unites the financial, operational, and commercial data sets required to support therapy access in the era of specialty and precision medicine. With ICyte, Life Sciences innovators are digitalizing labor-intensive processes – freeing up their best talent to identify and resolve coverage and availability hurdles and to manage pricing and forecasting complexity. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, with offices in Ambler, PA; Raleigh, NC, and Pune, India. For more information, visit www.integrichain.com, or follow us on Twitter @IntegriChain and LinkedIn.
Contact Jennifer Guinan, Sage Strategic Marketing, 610.410.8111, Jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List
